Clinical Epidemiology & Biostatistics



Mark Oremus

BA (McGill), MA (Concordia), MSc (McGill), PhD (McGill)

McLaughlin Foundation Professor of Population and Public Health & Associate Professor,
Department of Clinical Epidemiology & Biostatistics

Associate Scientific Director, Canadian Longitudinal Study on Aging

Associate Researcher, Gilbrea Centre for Studies in Aging

905.525.9140 x22437
905.522.7681
oremusm@mcmaster.ca

McMaster University
DTC Building, Room 308
1280 Main Street West
Hamilton, ON, Canada,
L8S 4L8

Office Location: Downtown Centre
50 Main Street East, Room 308
Hamilton, Ontario, Canada, L8N 1E9

Administrative Assistant: Leah Macdonald
905.525.9140 x22882
905.522.7681
lmacdon@mcmaster.ca

Academic Interests

Population and public health, aging, dementia, caregiving, knowledge transfer, questionnaire design and administration, systematic reviews, measuring drug efficacy, health economics, health policy.

Selected Publications

    1. Oremus M, Tarride JE, Clayton N, Canadian Willingness-to-Pay Study Group, Raina P. Health utility scores in Alzheimer's disease: differences based on calculation with American and Canadian preference weights. Value Health. 2014;17(1):77-83.
    2. Oremus M, Postuma R, Griffith L, Balion C, Wolfson C, Kirkland S, Patterson C, Shannon HS, CLSA Algorithms Validation Group, Raina P. Validating chronic disease ascertainment algorithms for use in the Canadian Longitudinal Study on Aging. Can J Aging. 2013;32(3):232-239.
    3. Oremus M, Tarride JE, Pullenayegum E, Clayton N, Canadian Willingness-to-pay Study Group, Raina P. Patients’ willingness-to-pay for an Alzheimer’s disease medication in Canada. The Patient. 2013;6(3):161-168.
    4. Oremus M, Tarride JE. Modeling cost-effectiveness of pharmaceuticals in Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):275-277.
    5. Oremus M, Oremus C, Hall GB, McKinnon MC, ECT & Cognition Systematic Review Team. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open. 2012;2(4): doi: 10.1136/bmjopen-2012-001368.
    6. Oremus M, Santaguida P, Walker K, Wishart LR, Siegel KL, Raina P. Studies of stroke rehabilitation therapies should report blinding and rationalize use of outcome measurement instruments. J Clin Epidemiol. 2012;65(4):368-374.
    7. Oremus M, Dayes I, Walker K, Raina P. Systematic review: conservative treatments for secondary lymphedema. BMC Cancer. 2012;12(1):6.
    8. Xie F, Oremus M, Gaebel K. Measuring health-related quality-of-life for Alzheimer’s disease using the general public. Qual Life Res. 2012;21(4):593-601.
    9. Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011;29(2):141-156.
    10. Oremus M, Raina P, Eva K, Lavis JN, Nair K, Lo A, Smith S.  Impact of clinician judgment on formulary committees' recommendations in Canada. J Health Serv Res Policy. 2010;15(2):98-105.

Search for citations for Dr. Oremus on PubMed